CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -568.53M | -581.60M | -488.30M | -467.80M | -385.66M |
| Total Depreciation and Amortization | 19.06M | 19.48M | 18.66M | 18.97M | 19.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 147.88M | 145.22M | 142.25M | 150.44M | 59.39M |
| Change in Net Operating Assets | 1.63M | 71.88M | 24.89M | -26.37M | 628.00K |
| Cash from Operations | -399.96M | -345.01M | -302.49M | -324.77M | -306.47M |
| Capital Expenditure | -1.21M | -914.00K | -651.00K | -796.00K | -1.39M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -421.58M | -30.89M | 37.48M | -4.76M | -201.05M |
| Cash from Investing | -422.79M | -31.81M | 36.82M | -5.55M | -202.44M |
| Total Debt Issued | 600.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 421.60M | 426.03M | 326.49M | 39.36M | 37.10M |
| Repurchase of Common Stock | -- | -- | -- | -- | -466.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.25M | -- | -- | -- | -- |
| Cash from Financing | 1.01B | 426.03M | 326.49M | 39.36M | 36.64M |
| Foreign Exchange rate Adjustments | 22.00K | 95.00K | 7.00K | 109.00K | 31.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 184.61M | 49.30M | 60.83M | -290.85M | -472.24M |